Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 10, 2014 - Issue 1
Submit an article Journal homepage
192
Views
3
CrossRef citations to date
0
Altmetric
Reviews

The intelligent use of systemic glucocorticoids in rheumatoid arthritis

Cecilia MerciecaUniversity of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol BS2 8HW, UKCorrespondence[email protected]
&
John R KirwanUniversity of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol BS2 8HW, UK
Pages 143-157 | Published online: 02 Dec 2013

References

  • Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of a hormone of the adrenal cortex (17-hydroxy-11 deoxycorticosterone: compound E) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis: preliminary report. Proc. Staff. Meet. Mayo Clinic 24(8), 181–197 (1949).
  • Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis. Rheum. 50(11), 3408–3417 (2004).
  • Thiele K, Buttgereit F, Huscher D, Zink A. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum. 53(5), 740–747 (2005).
  • Sokka T, Kautiainen H, Toloza S et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann. Rheum. Dis. 66(11), 1491–1496 (2007).
  • Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell Endocrinol. 275(1–2), 71–78 (2007).
  • Buttgereit F, Saag KG, Cutolo M, et al. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand. J. Rheumatol. 34(1), 14–21 (2005).
  • Buttgereit F, Seibel MJ, Bijlsma JW. Glucocorticoids. Clinical Immunology. Principles and Practice. (3rd Edition). Chapter 87 (2008).
  • Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc. Soc. Exp. Biol. Med. 217(4), 420–434 (1998).
  • Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J. Leukoc. Biol. 71(1), 9–15 (2002).
  • Wikstrom AC. Glucocorticoid action and novel mechanisms of steroid resistance: role of glucocorticoid receptor-interacting proteins for glucocorticoid responsiveness. J. Endocrinol. 178(3), 331–337 (2003).
  • Baschant U, Frappart L, Rauchhaus U et al. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl. Acad. Sci. USA. 108(48), 19317–19322 (2011).
  • Kleiman A, Hübner S, Rodriguez Parkitna JM et al. Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J. 26(2), 722–729 (2012).
  • Surjit M, Ganti KP, Mukherji A et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145(2), 224–241 (2011).
  • Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J. Endocrinol. 178(3), 347–355 (2003).
  • Goulding NJ, Flower RJ. Glucocorticoid biology - a molecular maze and clinical challenge in milestones in drug therapy. Glucocorticoids. Birkhäuser Verlag. 5 (2001).
  • Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96(1), 23–43 (2002).
  • Bartholome B, Spies CM, Gaber T et al. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB. J. 18(1), 70–80 (2004).
  • Löwenberg M, Verhaar AP, Bilderbeek J et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep. 2006 7(10), 1023–1029 (2006).
  • Harr MW, Rong Y, Bootman MD et al. Glucocorticoid-mediated inhibition of Lck modulates the pattern of T cell receptor-induced calcium signals by down-regulating inositol 1,4,5-trisphosphate receptors. J. Biol. Chem. 284(46), 31860–31871 (2009).
  • Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 67(6), 529–534 (2002).
  • Buttgereit F, da Silva JA, Boers M et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 61(8), 718–722 (2002).
  • Trikudanathan S, McMahon GT. Optimum management of glucocorticoid-treated patients. Nat. Clin. Pract. Endocrinol. Metab. 4(5), 262–271 (2008).
  • Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 356 (9224), 87–89 (2000).
  • Cutolo M, Foppiani L, Prete C et al. Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. J. Rheumatol. 26(2), 282–288 (1999).
  • Straub RH, Cutolo M. Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 44(3), 493–507 (2001).
  • Navarette MG, Brey RL. Neuropsychiatric systemic lupus erythematosus. Curr. Treat. Options Neurol. 2(5), 473–485 (2000).
  • Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst. Rev. CD001158 (2000).
  • Gotzsche PC Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ. 316(7134), 811–818 (1998).
  • Kirwan JR. Arthritis and Rheumatism Council low-dose glucocorticoid study group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N. Engl. J. Med. 333(3), 142–146 (1995).
  • Pincus T, Sokka T, Castrejón I, Cutolo M. Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res. 65(5), 729–736 (2013).
  • Verstappen SM, McCoy MJ, Roberts C et al. STIVEA investigators. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann. Rheum. Dis. 69(3), 503–509 (2010).
  • Corkill MM, Kirkham BW, Chikanza IC et al. Intramuscular depot methylprednisolone induction of chrysotherapy in rheumatoid arthritis: a 24-week randomized controlled trial. Br. J. Rheumatol. 29(4), 274–279 (1990).
  • Choy EH, Kingsley GH, Corkill MM, Panayi GS. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy. Br. J. Rheumatol. 32(8), 734–739 (1993).
  • Choy EH, Kingsley GH, Khoshaba B et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann. Rheum. Dis. 64(9), 1288–1293 (2005).
  • Kirwan JR. Glucocorticoid resistance in patients with rheumatoid arthritis. Scand. J. Rheumatol. 36(3), 165–166 (2007).
  • Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074), 309–318 (1997).
  • Jacobs JW, van Everdingen AA, Verstappen SM, Bijlsma JW. Follow up radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum. 54(5), 1422–1428 (2006).
  • van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann. Intern. Med. 136(1), 1–12 (2002).
  • Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 52(11), 3371–3380 (2005).
  • Svensson B, Boonen A, Albertsson K et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 52(11), 3360–3370 (2005).
  • Kirwan J, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst. Rev. CD006356 (2007).
  • Graudal N, Jurgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum. 62(10), 2852–2863 (2010).
  • Bakker MF, Jacobs JW, Welsing PM et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. A randomized trial. Ann. Intern. Med. 156(5), 329–333 (2012).
  • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146(6), 406–415 (2007).
  • Smolen JS, Landewé R, Breeveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964–975 (2010).
  • Landewé RB, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 46(2), 347–356 (2002).
  • Jacobs JW, Bijlsma JW. Innovative combination strategy to enhance effect and diminish adverse effects of glucocorticoids: another promise? Arthritis Res. Ther. 11(1), 105 (2009).
  • van Tuyl LHD, Boers M, Lems WF et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann. Rheum. Dis. 69(5), 807–812 (2010).
  • Hickling P, Jacoby RK, Kirwan JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br. J. Rheumatol. 37(9), 930–936 (1998).
  • Hafström I, Albertsson K, Boonen A et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann. Rheum. Dis. 68(4), 508–13 (2009).
  • Capell HA, Madhok R, Hunter JA et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann. Rheum. Dis. 63(7), 797–803 (2004).
  • Hansen M, Podenphant J, Florescu A et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann. Rheum. Dis. 58(11), 713–718 (1999).
  • Rheumatoid arthritis. The management of rheumatoid arthritis in adults. NICE clinical guideline 79, February 2009.
  • Durez P, Malghem J, Nzeusseu Toukap A et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 56(12), 3919–3927 (2007).
  • Frediani B, Falsetti P, Bisogno S et al. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J. Rheumatol. 31(6), 1083–1087 (2004).
  • Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 141(10), 764–770 (2004).
  • LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG. Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am. J. Med. 95(3):258–264 (1993).
  • van der Goes, Jacobs JW, Boers M et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 69(6), 1015–1021 (2010).
  • da Silva JAP, Jacobs JWG, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann. Rheum. Dis. 65(3), 285–293 (2006).
  • Bijlsma, JW, Saag, KG, Buttgereit F, da Silva JA. Developments in glucocorticoid therapy. Rheum. Dis. Clin. North. Am. 31(1), 1–17, vii (2005).
  • Hoes JN, Jacobs JW, Verstappen SM et al. Adverse events of low-to-medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann. Rheum. Dis. 68(12), 1833–1838 (2009).
  • Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15(6), 993–1000 (2000).
  • O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinol. 145(4), 1835–1841 (2004).
  • Dixon WG, Suissa S, Hudson M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res. Ther. 13(4), R139 (2011).
  • Ravindran V, Rachapalli S, Choy EH. Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatol. 48(7), 807–811 (2009).
  • Hoes, JN, Jacobs, JW, Boers, M et al. EULAR evidence- based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis. 66(12), 1560–1567 (2007).
  • van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 79(3), 129–137 (2006).
  • van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13(10), 777–787 (2002).
  • Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr. Rheumatol. Rep. 14(3), 224–230 (2012).
  • Haugeberg G, Uhlig T, Falch JA et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis. Rheum. 43(3), 522–530 (2000).
  • Book C, Karlsson M, Akesson K, Jacobsson L. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand. J. Rheumatol. 37(4), 248–254 (2008).
  • Forslind K, Keller C, Svensson B, Hafstrom I. Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J. Rheumatol. 30(12), 2590–2596 (2003).
  • Kanis JA, McCloskey EV, Johansson H et al. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos. Int. 19(10), 1395–1408 (2008).
  • McCloskey E, Kanis JA. FRAX updates 2012. Curr. Opin. Rheumatol. 24(5), 554–560 (2012).
  • Homik J, Cranney A, Shea B et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst. Rev. CD001347 (2000).
  • Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J. Bone Miner. Res. 17(8),1512–1526 (2002).
  • Peters MJ, Symmons DP, McCarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69(2), 325–331 (2010).
  • Klarenbeek NB, van der Kooij SM, Huizinga TJ et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann. Rheum. Dis. 69(7), 1342–1345 (2010).
  • Imai Y, Abe K, Sasaki S, et al. Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations. J. Hypertens. 7(2), 113–120 (1989).
  • Georgiadis AN, Papavasiliou EC, Lourida ES et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res. Ther. 8(3), R82 (2006).
  • Widdifield J, Bernatsky S, Paterson JM et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 65(3), 353–361 (2013).
  • Dixon WG, Abrahamowicz M, Beauchamp ME et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann. Rheum. Dis. 71(7), 1128–1133 (2012).
  • Buttgereit F, Doering G, Schaeffler A et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371(9608), 205–214 (2008).
  • Buttgereit F, Mehta DP, Kirwan JR et al. Low-dose glucocorticoid chronotherapy of rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann. Rheum. Dis. 72(2):204–210 (2013).
  • Alten R, Doring G, Cutolo M et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J. Rheumatol. 37(10), 2025–2031 (2010).
  • Bellamy N, Sothern RB, Campbell J, Buchanan WW. Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: relation between discomfort and disability. Ann. Rheum. Dis. 50(4), 243–248 (1991).
  • Westhoff G, Buttgereit F, Zink A. Fatigue and morning stiffness are correlated in early arthritis and both are substantially improved by glucocorticoids. Ann. Rheum. Dis. 70( Suppl. 3), 289 (2011).
  • Yazici Y, Pincus T, Kautiainen H, Sokka T. Morning stiffness in patients with early rheumatoid arthritis is associated more strongly with functional disability than with joint swelling and erythrocyte sedimentation rate. J. Rheumatol. 31(9), 1723–1726 (2004).
  • Arvidson NG, Gudbjornsson B, Elfman L et al. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann. Rheum. Dis. 53(8), 521–524 (1994).
  • Herzog ED, Geusz ME, Khalsa SB, Block GD. Circadian rhythms in mouse suprachiasmatic nucleus explants on multimicroelectrode plates. Brain Res. 757(2), 285–290 (1997).
  • Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 56(2), 399–408 (2007).
  • Crofford L, Kalogeras K, Mastorakos G et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J. Clin. Endocrinol. Metab. 82(4),1279–1283 (1997).
  • Perry M, Kirwan J, Jessop D, Hunt L. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. Ann. Rheum. Dis. 68(1), 63–68 (2009).
  • Jessop DS, Harbuz MS. A defect in cortisol production in rheumatoid arthritis: why are we still looking? Rheumatol. 44(9), 1097–1100 (2005).
  • De Silva M, Binder A, Hazleman B. The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. Ann. Rheum. Dis. 43(6), 790–793 (1984).
  • Arvidson NG, Gudbjornssen B, Larsson A, Hallgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann. Rheum. Dis. 56(1), 27–31 (1997).
  • Kirwan JR. Targeting the time of day for glucocorticoid delivery in rheumatoid arthritis. Int. J. Clin. Rheumatol. 6(3), 273–279 (2011).
  • Buttgereit F, Doering G, Schaeffler A et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann. Rheum. Dis. 69 (7), 275–280 (2010).
  • Clarke L, Jessop D, Hunt L, et al. Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int. J. Clin. Rheumatol. 6(2), 241–249 (2011).
  • Kirwan JR, Buttgereit F. Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. Rheumatol. 51( Suppl. 4), iv14–iv20 (2012).
  • Koning GA, Schiffelers RM, Wauben MH et al. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 54(4), 1198–1208 (2006).
  • Metselaar J, Wauben M, Wagenaar-Hilbers J et al. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum. 48(7), 2059–2066 (2003).
  • Avnir Y, Ulmansky R, Wasserman V et al. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum. 58(1), 119–129 (2008).
  • Rauchhaus U, Kinne RW, Pohlers D et al. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann. Rheum. Dis. 68(12), 1933–1934 (2009).
  • Ulmansky R, Turjeman K, Baru M et al. Glucocorticoids in nano-liposomes administered intravenously and subcutaneously to adjuvant arthritis rats are superior to the free drugs in suppressing arthritis and inflammatory cytokines. J. Control Release. 160(2), 299–305 (2012).
  • van den Hoven JM, Van Tomme SR, Metselaar JM et al. Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol. Pharm. 8(4), 1002–1015 (2011).
  • Barrera P. Long-circulating liposomal prednisolone versus pulse intramuscular methylprednisolone in patients with active rheumatoid arthritis. Arthritis Rheum. ( Suppl. 1), S453 (2008).
  • Paul-Clark MJ, Mancini L, Del Soldato P et al. Potent anti-arthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc. Natl. Acad. Sci. USA. 99(3), 1677–1682 (2002).
  • Paul-Clark MJ, Roviezzo F, Flower RJ et al. Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J. Immunol. 171(6), 3245–3252 (2003).
  • Zimmermann GR, Avery W, Finelli AL, et al. Selective amplification of glucocorticoid anti inflammatory activity through synergistic multitarget action of a combination drug. Arthritis Res. Ther. 11(1), R12 (2009).
  • Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler. Thromb. Vasc. Biol. 28(3), s39–s42 (2008).
  • Yao TC, Kuo ML, See LC et al. RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study. Arthritis Rheum. 54(8), 2585–2593 (2006).
  • Makowski GS, Ramsby ML. Autoactivation profiles of calcium-dependent matrix metalloproteinase-2 and -9 in inflammatory synovial fluid: effect of pyrophosphate and bisphosphonates. Clin. Chim. Acta. 358(1–2), 182–191 (2005).
  • Meijsing SH, Pufall MA, So AY et al. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science. 324(5925), 407–410 (2009).
  • Lin CW, Nakane M, Stashko M et al. Transactivation and repression properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5-(1-methylcyclohexen-3-y 1)-1H-[1]benzopyrano[3,4-f]quinoline (A276575) and its four stereoisomers. Mol. Pharmacol. 62(2), 297–303 (2002).
  • Schacke H, Schottelius A, Docke WD et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc. Natl. Acad. Sci. USA 101(1), 227–232 (2004).
  • Robertson S, Allie-Reid F, Vanden Berghe W et al. J. Biol. Chem. 285(11), 8061–8075 (2010).
  • De Bosscher K, Schmitz ML, Vanden Berghe W et al. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc. Natl. Acad. Sci. USA. 94(25), 13504–13509 (1997).
  • Dewint P, Gossye V, De Bosscher K et al. A plant-derived ligand favouring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J. Immunol. 180(4), 2608–2615 (2008).
  • Thiele S, Ziegler N, Tsourdi E et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J. Bone Mineral. Res. 27(11), 2242–2250 (2012).
  • Rauch A, Seitz S, Baschant U et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell. Metab. 11(6), 517–531 (2010).
  • D’Adamio F, Zollo O, Moraca R et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. Immunity. 7(6), 803–812(1997).
  • Di Marco B, Massetti M, Bruscoli S et al. Glucocorticoid-induced leucine zipper (GILZ)/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain. Nucleic Acids Res. 35(2), 517–528 (2007).
  • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann. Rheum. Dis. 66(9), 1227–1232 (2007).
  • Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford). 47(1), 59–64 (2008).
  • Bijlsma, van der Goes MC, Hoes JN et al. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann. NY. Acad. Sci. 1193, 123–126 (2010).
  • Kirwan J. Combination therapy including glucocorticoids: the new gold standard for early treatment in rheumatoid arthritis? Ann. Intern. Med. 156(5), 390–391 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.